Navneet Matharu
@navneetkmatharu
Followers
297
Following
951
Media
0
Statuses
214
RT @msirota84: Dear colleagues and friends, please join to Celebrate the life of Atul Butte on Saturday at 10am. Co-hosted by @ucsf, @Stanf….
0
18
0
RT @Bob_Wachter: There are few in this world who were such forces for good as @atulbutte. His dazzling intellect, relentless curiosity, gen….
0
59
0
RT @sajadtweets: Excited to share our new work on the dynamics of spatial 3D genome organization in relation to subnuclear compartments dur….
biorxiv.org
The nuclear genome is spatially organized into a three-dimensional (3D) architecture by physical association of large chromosomal domains with subnuclear compartments including the nuclear lamina at...
0
6
0
RT @NadavAhituv: Massively parallel jumping assay (MPJA). High throughput assay to assess the jumping potential of thousands of retrotransp….
biorxiv.org
The human genome contains millions of retrotransposons, several of which could become active due to somatic mutations having phenotypic consequences, including disease. However, it is not thoroughly...
0
11
0
RT @JRo_Hamilton: From exploring bio-entrepreneurship to securing $1 million in non-dilutive funding, the HS Chau WIES award transformed my….
0
5
0
Apply now! HS Chau IGI-WIES program is one of its kind opportunity for women in science to get a head start in entrepreneurial journey with the support of mentors and advisors. WIES immensely helped me with my entrepreneurial pursuits along with $1 million of non-dilutive funding.
0
0
5
0
4
0
RT @HershBhargava: Super excited to attend the 72nd Lindau Nobel Laureate Meeting thanks to the @UofCalifornia President's Fellowship @UCS….
0
3
0
RT @bakarlabs_uc: Our latest #TenantSpotlight is out! Learn about Regel Tx's co-founder & CSO @NavneetKMatharu and her mission to help pati….
0
1
0
RT @FamilieSCN2A: Today is Rare Disease Day! With less than 1000 known cases worldwide, SCN2A-related disorders (SRDs) are very RARE! #SCN2….
0
10
0
Pushing forward an effort that will impact patient lives! Thanks for the motivation.
RegEl Therapeutics announces T3 Platform & development pipeline as well as expanding BoD & SAB. CNS Pipe:. 🧬 #SCN1A. 🧬 #SCN2A. 🧬 #SYNGAP1 💥. Bravo @epilepsia @NadavAhituv @navneetkmatharu & team!.
0
2
16
RT @cureSYNGAP1: RegEl Therapeutics announces T3 Platform & development pipeline as well as expanding BoD & SAB. CNS Pipe:. 🧬 #SCN1A. 🧬 #S….
prnewswire.com
/PRNewswire/ -- Regel Therapeutics, a next generation gene therapy company utilizing proprietary technology to develop clinical products modulating gene...
0
21
0
RT @FamilieSCN2A: We are happy to share that Regel Therapeutics @navneetkmatharu @PerrySpratt has officially announced #SCN2A as a lead pro….
0
6
0
RT @sfbionetwork: SFBN Feed: Regel Therapeutics details its proprietary T3 platform and development pipeline on its newly launched website,….
0
1
0
RT @DahliaShaaban: A poignant, intimate piece from friend and parent advocate from @JMGraglia at @cureSYNGAP1 on the diagnosis, care, and t….
0
5
0
Congratulations Nadav!!!.
Extremely honored for this. Thanks to my lab, IHG members and staff and so many people at UCSF! Looking forward to advancing the IHG and genetics and genomics research at UCSF!.
0
0
2
RT @NadavAhituv: Extremely honored for this. Thanks to my lab, IHG members and staff and so many people at UCSF! Looking forward to advanci….
0
21
0
RT @JMGraglia: @cureSYNGAP1 @AmEpilepsySoc Love the collaboration. Please share @hcmefford @rhuganir @BCH_PoduriLab @BateupLab @GiorgiaQua….
0
4
0
RT @UrnovFyodor: Let me be BRUTALLY clear. The next step for this movement, superbly reported on by @mjnblack, is CRISPR "enhancement" of h….
0
40
0